MEP Antibacterial Screening Service
The methylerythritol phosphate (MEP) pathway, is utilized by most bacteria, including all Gram-negatives and many Gram-positives, and plant chloroplasts while the mevalonate pathway is found in humans, plant cytosol and some Gram-positive bacteria. Due to this natural distribution, the MEP pathway represents a promising target for development of novel antibacterial agents and herbicides.
- Echelon has 25 years of assay development expertise and 15 years experience in the MEP field.
- Your samples are cataloged and stored according to your requirements.
- The MEP Screening Service consists of two screens; a primary screen to identify “hits” of greater than 50% inhibition and a secondary screen to test any inhibitor identified in the first screen for specificity towards the MEP pathway.
- Usually, results are provided 2 weeks from receipt of samples. We can accommodate tighter schedules if needed.
Contact us for a quote on your custom assay service.
The MEP Screening Service consists of two parts:
- The “Primary Antibacterial Screen” identifies initial “hits”, >50% inhibition, at an initial concentration (usually 100 µg/mL). We screen up to 80 compounds per screen in duplicate.
- The “Secondary MEP-Selectivity Screen”: A potential inhibitor, identified above, is further tested against our engineered cell line under two growth conditions to determine if the potential inhibitor displays specificity toward the MEP pathway. Dose-response experiments are performed on 4 compounds per plate in duplicate and a MIC value (minimum inhibitory concentration), >90% inhibition, is assigned to each potential inhibitor.
Fill out the form below to receive a full quote for this service.
Publications for this service are based off of the MEP Synthase Inhibitor Screen (catalog number K-2000C), the product used for this assay service.
1) Bochar, D.A.; Freisen, J.A.; Stauffacher, C.V. and Rodwell, V.W.(1999) Comprehensive Natural Products Chemistry,(Cane, D. Ed.) Pergamon Press, Oxford, pp. 15-44.
2) Sacchettini, J.C. and Poulter, C.C. (1997) Science, 277(5333), 1788-9.
3) Testa, C.A.; Brown, M.J. (2003) Current Pharmceutical Biotechnology, 4, 248-259.
4) Koppisch, A.T.; Fox, D.T.; Blagg, B.; Poulter, C.D. (2002), Jan 8; 41 (1), 236-43.